Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Medical Devices; Third-Party Review Under the Food and Drug Administration Modernization Act, 72894-72895 [2013-29010]
Download as PDF
72894
Federal Register / Vol. 78, No. 233 / Wednesday, December 4, 2013 / Notices
relating to a distributed HCT/P that
relates to the core CGTP requirements,
if the deviation occurred in the
establishment’s facility or in a facility
that performed a manufacturing step for
the establishment under contract,
agreement or other arrangement, and to
report such HCT/P deviations within 45
days of the discovery of the event. Form
FDA 3486 is used to submit BPD reports
and HCT/P deviation reports.
Respondents to this collection of
information are (1) Licensed
manufacturers of biological products
other than human blood and blood
components; (2) licensed manufacturers
of blood and blood components
including Source Plasma; (3) unlicensed
registered blood establishments; (4)
transfusion services; and (5)
establishments that manufacture nonreproductive HCT/Ps regulated solely
under section 361 of the PHS Act as
described in § 1271.10. The number of
respondents and total annual responses
are based on the BPD reports and HCT/
P deviation reports FDA received in
fiscal year 2012. The number of licensed
manufacturers and total annual
responses under § 600.14 include the
estimates for BPD reports submitted to
both CBER and CDER. Based on the
information from industry, the
estimated average time to complete a
deviation report is 2 hours, which
includes a minimal one-time burden to
create a user account for those reports
submitted electronically. The
availability of the standardized report
form, Form FDA 3486, and the ability to
submit this report electronically to
CBER (CDER does not currently accept
electronic filings) further streamlines
the report submission process.
CBER developed a Web-based
addendum to Form FDA 3486 (Form
FDA 3486A) to provide additional
information when a BPD report has been
reviewed by FDA and evaluated as a
possible recall. The additional
information requested includes
information not contained in the Form
FDA 3486 such as: (1) Distribution
pattern; (2) method of consignee
notification; (3) consignee(s) of products
for further manufacture; (4) additional
product information; (5) updated
product disposition; and (6) industry
recall contacts. This information is
requested by CBER through email
notification to the submitter of the BPD
report. This information is used by
CBER for recall classification purposes.
At this time, Addendum 3486A is being
used only for those BPD reports
submitted under § 606.171. CBER
estimates that 5 percent of the total BPD
reports submitted to CBER under
§ 606.171 would need additional
information submitted in the
addendum. CBER further estimates that
it would take between 10 to 20 minutes
to complete the addendum. For
calculation purposes, CBER is using 15
minutes.
Activities such as investigating,
changing standard operating procedures
or processes, and followup are currently
required under 21 CFR part 211
(approved under OMB control number
0910–0139), part 606 (approved under
OMB control number 0910–0116), part
820 (approved under OMB control
number 0910–0073), and part 1271
(approved under OMB control number
0910–0543) and, therefore, are not
included in the burden calculation for
the separate requirement of submitting a
deviation report to FDA.
In the Federal Register of June 5, 2013
(78 FR 33846), FDA published a 60-day
notice requesting public comment on
the proposed collection of information.
No comments were received.
FDA estimates the burden of this
collection of information as follows:
TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN 1
21 CFR Section
Number of
respondents
Form FDA No.
600.14 ......................................................
606.171 ....................................................
1271.350(b) ..............................................
1271.350(b) ..............................................
3486
3486
3486
2 3486A
Number of
responses per
respondent
91
1,679
94
84
7.71
32.73
2.66
32.70
Total annual
responses
702
54,947
250
2,747
Average
burden per
response
2.0
2.0
2.0
0.25
Total ..................................................
Total hours
1,404
109,894
500
687
112,485
1 There
2 Five
are no capital costs or operating and maintenance costs associated with this collection of information.
percent of the number of respondents (1,679 × 0.05 = 84) and total annual responses to CBER (54,947 × 0.05 = 2,747).
Dated: November 27, 2013.
Leslie Kux,
Assistant Commissioner for Policy.
EMCDONALD on DSK67QTVN1PROD with NOTICES
BILLING CODE 4160–01–P
Food and Drug Administration
[Docket No. FDA–2013–N–0795]
[FR Doc. 2013–28990 Filed 12–3–13; 8:45 am]
information has been submitted to the
Office of Management and Budget
(OMB) for review and clearance under
the Paperwork Reduction Act of 1995.
DATES:
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Agency Information Collection
Activities; Submission for Office of
Management and Budget Review;
Comment Request; Medical Devices;
Third-Party Review Under the Food
and Drug Administration
Modernization Act
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) is announcing
that a proposed collection of
SUMMARY:
VerDate Mar<15>2010
17:09 Dec 03, 2013
Jkt 232001
PO 00000
Frm 00036
Fmt 4703
Sfmt 4703
Fax written comments on the
collection of information by January 3,
2014.
To ensure that comments on
the information collection are received,
OMB recommends that written
comments be faxed to the Office of
Information and Regulatory Affairs,
OMB, Attn: FDA Desk Officer, FAX:
202–395–7285, or emailed to oira_
submission@omb.eop.gov. All
comments should be identified with the
OMB control number 0910–0375. Also
include the FDA docket number found
in brackets in the heading of this
document.
ADDRESSES:
E:\FR\FM\04DEN1.SGM
04DEN1
Federal Register / Vol. 78, No. 233 / Wednesday, December 4, 2013 / Notices
FDA
PRA Staff, Office of Operations, Food
and Drug Administration, 1350 Piccard
Dr., PI50–400B, Rockville, MD 20850,
PRAStaff@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: In
compliance with 44 U.S.C. 3507, FDA
has submitted the following proposed
collection of information to OMB for
review and clearance.
FOR FURTHER INFORMATION CONTACT:
Medical Devices; Third-Party Review
Under the Food and Drug
Administration Modernization Act—
(OMB Control Number 0910–0375)—
Extension
Section 210 of the Food and Drug
Administration Modernization Act
(FDAMA) established section 523 of the
Federal Food, Drug, and Cosmetic Act
(21 U.S.C. 360m), directing FDA to
accredit persons in the private sector to
review certain premarket notifications
(510(k)s). Participation in this thirdparty review program by accredited
persons is entirely voluntary. A third
party wishing to participate will submit
a request for accreditation to FDA.
Accredited third-party reviewers have
the ability to review a manufacturer’s
510(k) submission for selected devices.
After reviewing a submission, the
reviewer will forward a copy of the
510(k) submission, along with the
reviewer’s documented review and
recommendation to FDA. Third-party
reviewers should maintain records of
their 510(k) reviews and a copy of the
510(k) for a reasonable period of time,
usually a period of 3 years.
72895
This information collection will allow
FDA to continue to implement the
accredited person review program
established by FDAMA and improve the
efficiency of 510(k) review for low- to
moderate-risk devices.
Respondents to this information
collection are businesses or other forprofit organizations.
In the Federal Register of July 9, 2013
(78 FR 41065), FDA published a 60-day
notice requesting public comment on
the proposed collection of information
to which one comment was received but
was unrelated to the information
collection.
FDA estimates the burden of this
collection of information as follows:
TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN
Number of
responses per
respondent
Number of
respondents
Activity
Requests for Accreditation .....................
510(k) Reviews Conducted by Accredited Third Parties ................................
Total annual
responses
Average burden
per response
1
1
1
24
24
10
26
260
40
10,400
Total ................................................
1 There
Total hours
10,424
are no capital costs or operating and maintenance costs associated with this collection of information.
510(k) Reviews Conducted by
Accredited Third Parties
According to FDA’s data, the number
of 510(k)s submitted for third-party
review is approximately 260 annually,
which is 26 annual reviews per each of
the 10 accredited reviewers.
TABLE 2—ESTIMATED ANNUAL RECORDKEEPING BURDEN
Activity
Number of recordkeepers
Number of records
per recordkeeper
Total annual
records
Average burden
per recordkeeping
Total hours
510(k) reviews ........................................
10
26
260
10
2,600
1 There
are no capital costs or operating and maintenance costs associated with this collection of information.
Third-party reviewers are required to
keep records of their review of each
submission. According to FDA’s data,
the Agency anticipates approximately
260 submissions of 510(k)s for thirdparty review per year.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Dated: November 27, 2013.
Leslie Kux,
Assistant Commissioner for Policy.
Agency Information Collection
Activities; Submission for Office of
Management and Budget Review;
Comment Request; Human Tissue
Intended for Transplantation
EMCDONALD on DSK67QTVN1PROD with NOTICES
[FR Doc. 2013–29010 Filed 12–3–13; 8:45 am]
BILLING CODE 4160–01–P
Food and Drug Administration
[Docket No. FDA–2013–N–0797]
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) is announcing
that a proposed collection of
information has been submitted to the
Office of Management and Budget
SUMMARY:
VerDate Mar<15>2010
17:09 Dec 03, 2013
Jkt 232001
PO 00000
Frm 00037
Fmt 4703
Sfmt 4703
(OMB) for review and clearance under
the Paperwork Reduction Act of 1995.
DATES: Fax written comments on the
collection of information by January 3,
2014.
ADDRESSES: To ensure that comments on
the information collection are received,
OMB recommends that written
comments be faxed to the Office of
Information and Regulatory Affairs,
OMB, Attn: FDA Desk Officer, FAX:
202–395–7285, or emailed to oira_
submission@omb.eop.gov. All
comments should be identified with the
OMB control number 0910–0302. Also
include the FDA docket number found
in brackets in the heading of this
document.
FDA
PRA Staff, Office of Operations, Food
FOR FURTHER INFORMATION CONTACT:
E:\FR\FM\04DEN1.SGM
04DEN1
Agencies
[Federal Register Volume 78, Number 233 (Wednesday, December 4, 2013)]
[Notices]
[Pages 72894-72895]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-29010]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2013-N-0795]
Agency Information Collection Activities; Submission for Office
of Management and Budget Review; Comment Request; Medical Devices;
Third-Party Review Under the Food and Drug Administration Modernization
Act
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing that a
proposed collection of information has been submitted to the Office of
Management and Budget (OMB) for review and clearance under the
Paperwork Reduction Act of 1995.
DATES: Fax written comments on the collection of information by January
3, 2014.
ADDRESSES: To ensure that comments on the information collection are
received, OMB recommends that written comments be faxed to the Office
of Information and Regulatory Affairs, OMB, Attn: FDA Desk Officer,
FAX: 202-395-7285, or emailed to oira_submission@omb.eop.gov. All
comments should be identified with the OMB control number 0910-0375.
Also include the FDA docket number found in brackets in the heading of
this document.
[[Page 72895]]
FOR FURTHER INFORMATION CONTACT: FDA PRA Staff, Office of Operations,
Food and Drug Administration, 1350 Piccard Dr., PI50-400B, Rockville,
MD 20850, PRAStaff@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: In compliance with 44 U.S.C. 3507, FDA has
submitted the following proposed collection of information to OMB for
review and clearance.
Medical Devices; Third-Party Review Under the Food and Drug
Administration Modernization Act--(OMB Control Number 0910-0375)--
Extension
Section 210 of the Food and Drug Administration Modernization Act
(FDAMA) established section 523 of the Federal Food, Drug, and Cosmetic
Act (21 U.S.C. 360m), directing FDA to accredit persons in the private
sector to review certain premarket notifications (510(k)s).
Participation in this third-party review program by accredited persons
is entirely voluntary. A third party wishing to participate will submit
a request for accreditation to FDA. Accredited third-party reviewers
have the ability to review a manufacturer's 510(k) submission for
selected devices. After reviewing a submission, the reviewer will
forward a copy of the 510(k) submission, along with the reviewer's
documented review and recommendation to FDA. Third-party reviewers
should maintain records of their 510(k) reviews and a copy of the
510(k) for a reasonable period of time, usually a period of 3 years.
This information collection will allow FDA to continue to implement
the accredited person review program established by FDAMA and improve
the efficiency of 510(k) review for low- to moderate-risk devices.
Respondents to this information collection are businesses or other
for-profit organizations.
In the Federal Register of July 9, 2013 (78 FR 41065), FDA
published a 60-day notice requesting public comment on the proposed
collection of information to which one comment was received but was
unrelated to the information collection.
FDA estimates the burden of this collection of information as
follows:
Table 1--Estimated Annual Reporting Burden
--------------------------------------------------------------------------------------------------------------------------------------------------------
Number of
Activity Number of responses per Total annual Average burden Total hours
respondents respondent responses per response
--------------------------------------------------------------------------------------------------------------------------------------------------------
Requests for Accreditation............................... 1 1 1 24 24
510(k) Reviews Conducted by Accredited Third Parties..... 10 26 260 40 10,400
----------------------------------------------------------------------------------------------
Total................................................ ................. ................. ................. ................. 10,424
--------------------------------------------------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of information.
510(k) Reviews Conducted by Accredited Third Parties
According to FDA's data, the number of 510(k)s submitted for third-
party review is approximately 260 annually, which is 26 annual reviews
per each of the 10 accredited reviewers.
Table 2--Estimated Annual Recordkeeping Burden
--------------------------------------------------------------------------------------------------------------------------------------------------------
Number of Number of records Total annual Average burden per
Activity recordkeepers per recordkeeper records recordkeeping Total hours
--------------------------------------------------------------------------------------------------------------------------------------------------------
510(k) reviews...................................... 10 26 260 10 2,600
--------------------------------------------------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of information.
Third-party reviewers are required to keep records of their review
of each submission. According to FDA's data, the Agency anticipates
approximately 260 submissions of 510(k)s for third-party review per
year.
Dated: November 27, 2013.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2013-29010 Filed 12-3-13; 8:45 am]
BILLING CODE 4160-01-P